Hyperfine reiterates $20M-$22M 2026 revenue outlook while targeting contrast FDA submission by year-end 2026 (NASDAQ:HYPR)
· seekingalpha.com
Hyperfine (HYPR) Q2 2026 earnings call recap: $3.9M revenue, 12 systems, 50%+ margins, guidance and catalysts in IDNs, offices and Europe.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...